Join
Live feed
·
PRReleasevia Quantisnow
Glaukos Corporation logo

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

ByQuantisnow·Wall Street's wire, on your screen.
GKOS· Glaukos Corporation
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GKOS (Glaukos Corporation) and more on Quantisnow.